Neurosense Therapeutics Ltd. (NRSN)
NASDAQ:NRSN
Want to see NRSN full AI Analyst Report?
Top Page
Neurosense Therapeutics Ltd.
(NASDAQ:NRSN)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.68
▼(-3.66% Downside)
Action:Reiterated
Date:04/29/26
The score is primarily weighed down by weak financial performance (no revenue, significant ongoing losses, negative free cash flow, and negative equity/declining assets). Technicals are mixed with longer-term downtrend signals, and valuation is not supportive due to negative earnings and no dividend.
Positive Factors
Strong global patent estate
A broad, multi-jurisdictional patent portfolio for PrimeC (composition, formulation, manufacturing and use) creates a durable exclusivity moat through 2042. This materially strengthens commercialization leverage, bargaining power with partners, and long-term pricing/profitability prospects if Phase 3 succeeds.
Negative Factors
Pre-revenue with persistent operating losses
Being pre-revenue with expanding multi-year operating losses means the business lacks internal cash generation and must rely on external financing until commercialization. This structural gap increases dilution risk, constrains strategic choices and places long-term viability on successful late-stage outcomes or partner deals.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong global patent estate
A broad, multi-jurisdictional patent portfolio for PrimeC (composition, formulation, manufacturing and use) creates a durable exclusivity moat through 2042. This materially strengthens commercialization leverage, bargaining power with partners, and long-term pricing/profitability prospects if Phase 3 succeeds.
Read all positive factors
Neurosense Therapeutics Ltd. (NRSN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$28.44M
Dividend YieldN/A
Average Volume (3M)944.42K
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding35,349,810
10 Day Avg. Volume256,142
30 Day Avg. Volume944,423
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-12.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.55
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.03
Forecast
1Y Price Target
$6.00Price Target Upside745.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.39
Revenue Forecast (FY)$714.07K
Neurosense Therapeutics Ltd. Business Overview & Revenue Model
Company Description
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading ...
How the Company Makes Money
null...
Neurosense Therapeutics Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
22
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -89.00K | -3.00K |
| EBITDA | -8.55M | -11.11M | -9.88M | -9.64M | -12.23M | -2.88M |
| Net Income | -8.66M | -11.13M | -10.21M | -10.11M | -12.34M | -4.04M |
Balance Sheet | ||||||
| Total Assets | 1.68M | 1.03M | 4.58M | 3.19M | 7.71M | 11.43M |
| Cash, Cash Equivalents and Short-Term Investments | 666.00K | 166.00K | 3.38M | 2.64M | 7.09M | 11.06M |
| Total Debt | 0.00 | 170.00K | 73.00K | 142.00K | 211.00K | 1.83M |
| Total Liabilities | 2.20M | 2.59M | 1.99M | 4.94M | 2.09M | 2.42M |
| Stockholders Equity | -519.00K | -1.56M | 2.58M | -1.76M | 5.62M | 9.01M |
Cash Flow | ||||||
| Free Cash Flow | -2.00K | -7.68M | -10.14M | -8.38M | -7.66M | -1.56M |
| Operating Cash Flow | -2.00K | -7.67M | -10.13M | -8.35M | -7.59M | -1.54M |
| Investing Cash Flow | -7.00 | -8.00K | 1.00K | 3.47M | -3.54M | -17.00K |
| Financing Cash Flow | 651.00 | 4.43M | 10.91M | 3.98M | 3.69M | 11.90M |
Neurosense Therapeutics Ltd. Technical Analysis
Positive
0.71
Price Trends
0.78
Positive
0.82
Negative
0.94
Negative
Market Momentum
-0.02
Positive
53.93
Neutral
41.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRSN, the sentiment is Positive. The current price of 0.71 is below the 20-day moving average (MA) of 0.78, below the 50-day MA of 0.78, and below the 200-day MA of 0.94, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 53.93 is Neutral, neither overbought nor oversold. The STOCH value of 41.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NRSN.
Neurosense Therapeutics Ltd. Risk Analysis
Neurosense Therapeutics Ltd. disclosed 69 risk factors in its most recent earnings report. Neurosense Therapeutics Ltd. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
If we fail to maintain compliance with Nasdaq's continued listing requirements, our shares may be delisted from the Nasdaq Capital Market. Q4, 2023
2.
If a United States person is treated as owning at least 10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences. Q4, 2023
3.
Environmental, social and corporate governance, or ESG, issues, including those related to climate change and sustainability, may have an adverse effect on our business, financial condition and results of operations and damage our reputation. Q4, 2023
Neurosense Therapeutics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $88.55M | -10.75 | -185.74% | ― | 45.88% | 34.17% | |
45 Neutral | $318.30M | -9.37 | -56.32% | ― | ― | 43.48% | |
44 Neutral | $28.44M | -3.14 | 9999.00% | ― | ― | ― | |
42 Neutral | $14.72M | -1.50 | -108.76% | ― | ― | 5.12% | |
41 Neutral | $4.86M | -0.35 | -92.74% | ― | -84.26% | 14.73% |
* Healthcare Sector Average
NRSN
Neurosense Therapeutics Ltd.
0.80
-1.55
-65.79%
TENX
Tenax Therapeutics
12.00
6.21
107.25%
CLGN
Collplant Holdings
0.34
-1.13
-77.07%
XCUR
Exicure
2.31
-5.16
-69.08%
NRXS
NeurAxis, Inc.
7.15
4.61
181.50%
Neurosense Therapeutics Ltd. Corporate Events
NeuroSense Secures South Korean Patent for ALS Drug Candidate PrimeC
Jun 11, 2026
NeuroSense Therapeutics Ltd., a late-clinical stage biotech focused on treatments for severe neurodegenerative diseases such as ALS and Alzheimer’s, is advancing PrimeC, an oral fixed-dose combination therapy designed to act on several key m...
NeuroSense Therapeutics Wins Key Japanese Patent for ALS Drug PrimeC
Jun 9, 2026
NeuroSense Therapeutics announced on June 9, 2026 that the Japan Patent Office has granted Japanese Patent 7857044 covering the composition and manufacturing process of PrimeC, its lead drug candidate for ALS, extending protection for the synchron...
NeuroSense Therapeutics Advances Canadian Regulatory Talks on ALS Drug PrimeC
Jun 8, 2026
On June 8, 2026, NeuroSense Therapeutics reported that it recently held a constructive meeting with Health Canada to discuss potential regulatory pathways for PrimeC, its investigational ALS therapy. The company presented additional data requested...
NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price
Apr 28, 2026
On April 28, 2026, NeuroSense Therapeutics Ltd. announced it had entered into a definitive agreement for a $600,000 insider-led private investment in public equity financing, selling 750,000 ordinary shares at $0.80 per share, a 6.7% premium to th...
NeuroSense Therapeutics Transitions Chief Medical Officer to Advisory Role Ahead of Key PrimeC Milestones
Apr 24, 2026
On April 24, 2026, NeuroSense Therapeutics announced that Chief Medical Officer Dr. Ferenc Tracik will step down from his role, effective April 27, 2026, and transition to serving the company as an independent advisor. The company emphasized that ...
NeuroSense Wins Long-Term Brazilian Patent Protection for ALS Drug PrimeC
Apr 6, 2026
On April 6, 2026, NeuroSense Therapeutics announced that Brazil’s patent office granted a patent covering the composition of its lead drug candidate PrimeC, following earlier patent approvals in the U.S. and Australia. The Brazilian patent s...
NeuroSense Therapeutics Faces Nasdaq Deficiency Notices but Retains Listing Status
Apr 3, 2026
On April 3, 2026, NeuroSense Therapeutics disclosed that it received two Nasdaq notices on April 2 stating its shares failed to meet minimum bid price and market value of listed securities requirements between February 18 and March 31, 2026. The c...
NeuroSense Therapeutics Posts 2025 Results as PrimeC Advances Toward Phase 3 ALS Trial
Mar 31, 2026
On March 31, 2026, NeuroSense Therapeutics reported its financial results for the year ended December 31, 2025 and detailed a pivotal year in which PrimeC progressed from a successful Phase 2b ALS program into a late-stage clinical asset with FDA ...
NeuroSense Reschedules Health Canada Meeting as PrimeC Data Package Strengthens
Mar 24, 2026
On March 24, 2026, NeuroSense Therapeutics reported that it has rescheduled a pre-New Drug Submission meeting with Health Canada to May 2026 to incorporate new clinical, biomarker and survival data for its ALS and Alzheimer’s candidate Prime...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.